콘텐츠로 건너뛰기
Merck

N0550000

Neostigmine methyl sulfate

European Pharmacopoeia (EP) Reference Standard

동의어(들):

3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

50 MG

₩220,763

₩220,763


구입 가능 여부는 고객센터에 문의하십시오.

벌크 견적 요청하기

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C13H22N2O6S
CAS 번호:
Molecular Weight:
334.39
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

다음으로 건너뛰기

기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

제품 이름

Neostigmine methyl sulfate, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1

SMILES string

COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C

InChI key

OSZNNLWOYWAHSS-UHFFFAOYSA-M

grade

pharmaceutical primary standard

API family

neostigmine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ACHE(43)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

유사한 품목 비교

전체 비교 보기

차이점 표시

1 of 4

이 품목
1460000N2126N0500000
manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

-

grade

pharmaceutical primary standard

format

neat

format

neat

format

-

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

API family

neostigmine

API family

neostigmine

API family

-

API family

neostigmine

Gene Information

human ... ACHE(43)

Gene Information

human ... ACHE(43)

Gene Information

human ... ACHE(43)

Gene Information

human ... ACHE(43)

Application

Neostigmine methyl sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.
Reversible inhibitor of acetylcholinesterase; does not cross the blood-brain barrier.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

저장 등급

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review
M O Akinwale et al.
African journal of medicine and medical sciences, 41(2), 231-237 (2012-11-29)
The spinal route of analgesia has consolidated its place as a major modality in the management of both acute and chronic pain. The search for ideal additives to local anaesthetic agents to prolong the analgesic effects poses a challenge to
Comparing sugammadex and neostigmine reversal of neuromuscular blockade in laparoscopic surgery.
D Jain et al.
Anaesthesia, 68(3), 306-307 (2013-02-07)
G V Cammu et al.
Anaesthesia and intensive care, 40(6), 999-1006 (2012-12-01)
Six years ago, a study performed in our department reported that the incidence of postoperative residual curarisation (PORC) was 39%. The reassessment of neuromuscular monitoring and reversal of neuromuscular block in routine anaesthetic practice is relevant now that sugammadex has
Tetsufumi Sato et al.
Masui. The Japanese journal of anesthesiology, 62(1), 19-26 (2013-02-26)
Anticholinesterase, such as neostigmine, was used to be a standard drug at the end of surgery for reversal of nondepolarizing neuromuscular block. Neostigmine decreases the metabolism of acetylcholine (ACh) at the neuromuscular junction and allows its concentration to increase and

질문

후기

평점 값 없음

활성 필터

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.